

# World Journal of *Gastroenterology*

World J Gastroenterol 2018 December 28; 24(48): 5415-5536



**EDITORIAL**

- 5415 Role of cenicriviroc in the management of nonalcoholic fatty liver disease  
*Neokosmidis G, Tziomalos K*

**REVIEW**

- 5418 Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens  
*Wagner S, Mullins CS, Linnebacher M*

**MINIREVIEWS**

- 5433 Checkpoint inhibitors: What gastroenterologists need to know  
*Ahmed M*
- 5439 Virtual reality simulation in endoscopy training: Current evidence and future directions  
*Mahmood T, Scaffidi MA, Khan R, Grover SC*
- 5446 Quality of life in patients with minimal hepatic encephalopathy  
*Ridola L, Nardelli S, Gioia S, Riggio O*
- 5454 Post-translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal cancer: An update  
*Jaén RI, Prieto P, Casado M, Martín-Sanz P, Boscá L*

**ORIGINAL ARTICLE****Basic Study**

- 5462 Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine  
*Drmic D, Samara M, Vidovic T, Malekinusic D, Antunovic M, Vrdoljak B, Ruzman J, Milkovic Perisa M, Horvat Pavlov K, Jeyakumar J, Seiwerth S, Sikiric P*
- 5477 Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease  
*Saeed WK, Jun DW, Jang K, Ahn SB, Oh JH, Chae YJ, Lee JS, Kang HT*
- 5491 Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody  
*Aung W, Tsuji AB, Sugyo A, Takashima H, Yasunaga M, Matsumura Y, Higashi T*
- 5505 Integrated metabolomic profiling for analysis of antilipidemic effects of *Polygonatum kingianum* extract on dyslipidemia in rats  
*Yang XX, Wei JD, Mu JK, Liu X, Dong JC, Zeng LX, Gu W, Li JP, Yu J*

**Retrospective Study**

- 5288** Safety of hepatitis B virus core antigen-positive grafts in liver transplantation: A single-center experience in China

*Lei M, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Wu H, Xu MQ, Chen ZY, Wei YG*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Harald Peter Hoensch, MD, Emeritus Professor, Marien Hospital Medical Department, Private Practice in Internal Medicine and Gastroenterology, Darmstadt D-64285, Germany

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 642 experts in gastroenterology and hepatology from 59 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2018 edition of Journal Citation Reports® cites the 2017 impact factor for *WJG* as 3.300 (5-year impact factor: 3.387), ranking *WJG* as 35<sup>th</sup> among 80 journals in gastroenterology and hepatology (quartile in category Q2).

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Shu-Yu Yin*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Rao-Yu Ma*  
**Proofing Editorial Office Director:** *Ze-Mao Gong*

**NAME OF JOURNAL**  
*World Journal of Gastroenterology*

**ISSN**  
 ISSN 1007-9327 (print)  
 ISSN 2219-2840 (online)

**LAUNCH DATE**  
 October 1, 1995

**FREQUENCY**  
 Weekly

**EDITORS-IN-CHIEF**  
**Andrzej S Tarnawski, MD, PhD, DSc (Med),**  
**Professor of Medicine, Chief Gastroenterology, VA**  
 Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach, CA 90822, United States

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <https://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**  
 Ze-Mao Gong, Director  
*World Journal of Gastroenterology*  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
 Help Desk: <https://www.f0publishing.com/helpdesk>  
<https://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
 Help Desk: <https://www.f0publishing.com/helpdesk>  
<https://www.wjgnet.com>

**PUBLICATION DATE**  
 December 28, 2018

**COPYRIGHT**  
 © 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at <https://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<https://www.f0publishing.com>

## Basic Study

# Integrated metabolomic profiling for analysis of antilipidemic effects of *Polygonatum kingianum* extract on dyslipidemia in rats

Xing-Xin Yang, Jia-Di Wei, Jian-Kang Mu, Xin Liu, Jin-Cai Dong, Lin-Xi Zeng, Wen Gu, Jing-Ping Li, Jie Yu

Xing-Xin Yang, Jia-Di Wei, Jian-Kang Mu, Jin-Cai Dong, Lin-Xi Zeng, Wen Gu, Jing-Ping Li, Jie Yu, College of Pharmaceutical Science, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China

Xin Liu, Beijing Entry-Exit Inspection and Quarantine Bureau, Beijing 100026, China

ORCID number: Xing-Xin Yang (0000-0001-6594-772X); Jia-Di Wei (0000-0002-8108-0457); Jian-Kang Mu (0000-0001-9189-2515); Xin Liu (0000-0003-4788-5275); Jin-Cai Dong (0000-0001-6909-9676); Lin-Xi Zeng (0000-0002-3234-2377); Wen Gu (0000-0003-3766-5180); Jing-Ping Li (0000-0002-7452-6342); Jie Yu (0000-0001-8100-8896).

**Author contributions:** Yang XX and Yu J designed the research; Yang XX, Wei JD and Dong JC performed the research; Liu X contributed analytic tools; Zeng LX, Gu W and Li JP analyzed the data; Yang XX, Wei JD and Mu JK wrote the paper.

**Supported by** the National Natural Science Foundation of China, No. 81660596 and No. 81760733; the Application and Basis Research Project of Yunnan, China, No. 2016FD050 and No. 2017FF117-013; and the Fund for Young and Middle-aged Academic and Technological Leaders of Yunnan, No. 2015HB053.

**Institutional animal care and use committee statement:** Approval from the Institutional Ethical Committee on Animal Care and Experimentations of Yunnan University of Traditional Chinese Medicine was obtained for this study.

**Conflict-of-interest statement:** The authors declare that there is no duality of interest associated with this manuscript.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors had read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external

reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** Jie Yu, PhD, Professor, College of Pharmaceutical Science, Yunnan University of Traditional Chinese Medicine, 1076 Yuhua Road, Kunming 650500, Yunnan Province, China. [cz.yujie@gmail.com](mailto:cz.yujie@gmail.com)  
Telephone: +86-871-65933303  
Fax: +86-871-65933303

**Received:** September 25, 2018

**Peer-review started:** September 25, 2018

**First decision:** October 24, 2018

**Revised:** October 31, 2018

**Accepted:** November 16, 2018

**Article in press:** November 16, 2018

**Published online:** December 28, 2018

## Abstract

### AIM

To identify the effects and mechanism of action of *Polygonatum kingianum* (*P. kingianum*) on dyslipidemia in rats using an integrated untargeted metabolomic method.

### METHODS

A rat model of dyslipidemia was induced with a high-fat diet (HFD) and rats were given *P. kingianum* [4 g/(kg·d)] intragastrically for 14 wk. Changes in serum and hepatic lipid parameters were evaluated. Metabolites in serum, urine and liver samples were profiled using ultra-high



performance liquid chromatography/mass spectrometry followed by multivariate statistical analysis to identify potential biomarkers and metabolic pathways.

## RESULTS

*P. kingianum* significantly inhibited the HFD-induced increase in total cholesterol and triglyceride in the liver and serum. *P. kingianum* also significantly regulated metabolites in the analyzed samples toward normal status. Nineteen, twenty-four and thirty-eight potential biomarkers were identified in serum, urine and liver samples, respectively. These biomarkers involved biosynthesis of phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine, along with metabolism of tryptophan, tyrosine, phenylalanine, starch, sucrose, glycerophospholipid, arachidonic acid, linoleic acid, nicotinate, nicotinamide and sphingolipid.

## CONCLUSION

*P. kingianum* alleviates HFD-induced dyslipidemia by regulating many endogenous metabolites in serum, urine and liver samples. Collectively, our findings suggest that *P. kingianum* may be a promising lipid regulator to treat dyslipidemia and associated diseases.

**Key words:** Dyslipidemia; Lipid regulation; Metabolomics; Multivariate statistical analysis; *Polygonatum kingianum*; Ultra-high performance liquid chromatography/mass spectrometry

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We investigated the effects and the underlying mechanism of action of *Polygonatum kingianum* (*P. kingianum*) on high-fat diet (HFD)-induced dyslipidemia in rats using an integrated untargeted metabolomic method. The results indicated that *P. kingianum* alleviated HFD-induced dyslipidemia by regulating a large number of endogenous metabolites in serum, urine and liver. This involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and tryptophan, tyrosine, phenylalanine, starch, sucrose, glycerophospholipid, arachidonic acid, linoleic acid, nicotinate, nicotinamide and sphingolipid metabolism. *P. kingianum* may be a promising lipid regulator to remedy dyslipidemia and further alleviate its related diseases.

Yang XX, Wei JD, Mu JK, Liu X, Dong JC, Zeng LX, Gu W, Li JP, Yu J. Integrated metabolomic profiling for analysis of antilipidemic effects of *Polygonatum kingianum* extract on dyslipidemia in rats. *World J Gastroenterol* 2018; 24(48): 5505-5524  
URL: <https://www.wjgnet.com/1007-9327/full/v24/i48/5505.htm>  
DOI: <https://dx.doi.org/10.3748/wjg.v24.i48.5505>

## INTRODUCTION


Dyslipidemia is a core characteristic of the metabolic

syndrome, and is an important risk factor for atherosclerosis, coronary heart disease, stroke and other cardiovascular and cerebrovascular diseases. It is also closely related to many significant diseases such as diabetes and nephropathy<sup>[1]</sup>. Dyslipidemia is divided into two types, referred to as primary and secondary dyslipidemia. Primary dyslipidemia has a genetic history and may be caused by congenital enzyme defects. Secondary dyslipidemia is usually present in patients with diseases such as diabetes mellitus, hypothyroidism, nephrotic syndrome, biliary obstruction, pancreatitis, gout, alcoholism, and various liver disorders<sup>[2]</sup>. The improvement in living standards and associated lifestyle changes have led to dyslipidemia being considered one of the most important risk factors for metabolic diseases worldwide<sup>[3]</sup>. Therefore, management of dyslipidemia is of vital importance to prevent and cure a variety of acute and chronic human diseases.

The commonly used lipid regulators include statins, fibrates, nicotinic acid and variants, bile acid sequestrants and inhibitors of cholesterol absorption. These drugs can be effective for treating dyslipidemia, but have significant adverse effect profiles<sup>[4]</sup>. For example, statins may increase blood glucose concentrations, cause rhabdomyolysis or damage the liver and kidneys<sup>[5]</sup>. Traditional Chinese medicines (TCMs) are one of the world's oldest herbal medicines and have been applied extensively by TCM practitioners for thousands of years<sup>[6]</sup>. TCMs have an indispensable role in the prevention and treatment of human diseases, especially those that are complicated and chronic<sup>[7]</sup>. As a complementary therapy technique with fewer side effects than Western medicines, TCMs have been employed widely to regulate lipid metabolic disorders<sup>[8]</sup>. Thus, TCMs may serve as the basis for development of new lipid-regulating drugs or health products.

*Rhizoma polygonati*, first recorded in *Mingyi Bielu* in 220-450 AD (written by Hong-Jing Tao), has been used as a TCM and nutritional food for over 2000 years. *Polygonatum kingianum* Coll. et Hemsl., *Polygonatum sibiricum* Red. and *Polygonatum cyrtoneura* Hua are described in the Chinese Pharmacopoeia (2015 edition) as legal sources of *Rhizoma polygonati*. *Polygonatum kingianum* (*P. kingianum*; Figure 1) is mainly distributed in the Chinese provinces of Yunnan, Sichuan, Guizhou and Guangxi. It is mainly comprised of saponins and polysaccharides, and has pharmacological activities that include immune system stimulation, anti-aging effects and blood glucose regulation<sup>[9,10]</sup>. Our previous research showed that the total saponins and total polysaccharides from *P. kingianum* had blood glucose and lipid regulating activities<sup>[11,12]</sup>. However, the lipid-regulating effects of *P. kingianum* and the mechanism for these remain unclear.

Metabolomics can comprehensively characterize small molecule metabolites in biological systems. It can also provide an overview of metabolic status and global biochemical events after external stimulation such as in disease models and after drug treatment<sup>[13]</sup>. Metabolomics is a novel method in pharmacological and phar-



**Figure 1** *Polygonatum kingianum*. A: Whole plant photograph of *Polygonatum kingianum* (*P. kingianum*); B: Rhizome of *P. kingianum*, which represents the medicinal part of this plant used in this study.

macodynamic studies that is increasingly employed to assess the therapeutic and toxic effects of herbal TCMS and TCM prescriptions, and their mechanism of action<sup>[14]</sup>.

In the present study, we investigated the lipid-regulating effects and the underlying mechanism of action of *P. kingianum* on high-fat diet (HFD)-induced dyslipidemia in rats. An integrated untargeted metabolomic method was used, which was based on ultra-high performance liquid chromatography/mass spectrometry (UHPLC/MS) analysis of serum, urine and liver samples (Figure 2). The results indicated that *P. kingianum* alleviated HFD-induced dyslipidemia by regulating many endogenous metabolites in serum, urine and liver samples. Taken together, these findings indicated that *P. kingianum* may be a promising lipid regulator to treat dyslipidemia and further alleviate associated diseases.

## MATERIALS AND METHODS

### Chemicals, reagents and materials

Kits for quantifying triglyceride (TG) and total cholesterol (TC) concentrations were purchased from ZhongshengBei Biotech Co., Ltd. (Beijing, China). Bicinchoninic Acid (BCA) Protein Determination Kit was obtained from Beyotime Institute of Biotechnology (Shanghai, China). Simvastatin was purchased from Hangzhou Merck East Pharmaceutical Co., Ltd. (Hangzhou, China). HPLC-grade formic acid and acetonitrile were acquired from Merck (Darmstadt, Germany). Basal rodent diet (calories provided from carbohydrates, proteins and fat were 62%, 26% and 12%, respectively) was obtained from Suzhou Shuangshi Experimental Animal Feed Technology Co., Ltd. (Suzhou, China). Cholesterol, refined lard, and eggs were supplied by Beijing Boao Extension Co., Ltd. (Beijing, China), Sichuan Green Island Co., Ltd. (Chengdu, China) and Wal-Mart Supermarket (Kunming, China), respectively. High-purity deionized water was purified using a Milli-Q system (Millipore, Bedford, MA, United States). All other reagents were of analytical grade or higher. The rhizome of *P. kingianum* was purchased from Wenshan Shengnong Trueborn Medicinal Materials Cultivation Cooperation Society (Wenshan, China) on 07

April 2017. Samples were authenticated by Professor Jie Yu and a voucher specimen (No. 8426) was deposited in the Key Laboratory of Preventing Metabolic Diseases of Traditional Chinese Medicine, Yunnan University of Traditional Chinese Medicine (Kunming, China).

### Preparation of *P. kingianum* extract


*P. kingianum* rhizome was processed according to regulations in the Chinese Pharmacopoeia (2015 edition). Briefly, fresh *P. kingianum* rhizome was separated from fibrous roots, washed, cut into thick slices and dried at 50 °C. The dried materials were then infiltrated in a 5-fold volume of Shaoxing rice wine (Beijing Ershang Wangzhihe Food Co., Ltd., Beijing, China), and then placed in a steam sterilizer (LDZX-50 KBS, Shanghai Shenan Medical Instrument Factory, Shanghai, China) at 120 °C for 2.5 h. After cooling for 3 h, the steamed materials were dried at 60 °C.

The steamed and dried *P. kingianum* sample was pulverized, immersed in a 7-fold volume of water for 30 min and then decocted with water for 60 min. The filtrates were collected after leaching. The dregs were decocted successively with a 7-fold volume of water for a further 60 min, and the extracted liquids filtered. The two filtrates were then combined and condensed using an R-210 rotatory evaporator (Büchi Labortechnik AG, Flawil, Switzerland) under reduced pressure at 50 °C. Finally, the concentrates were lyophilized to a powder using a FD5-3 freeze dryer (SIM International Group Co. Ltd., Newark, DE, United States). The obtained sample powder was stored in a desiccator at room temperature until use.

### Animal experiments

Healthy male Sprague-Dawley rats (200 ± 50 g) were obtained from Dashuo Biotech. Co., Ltd. (Chengdu, China). They were adjusted to a controlled environment (22 ± 1 °C temperature; 60% ± 10% humidity; and a 12 h/12 h light/dark cycle) with free access to water and a commercial laboratory complete food. Experiments complied with the Guide for the Care and Use of Laboratory Animals as published by the United States of America National Institutes of Health and specifically approved by the Institutional Ethical Committee on Animal Care and Experimentations of Yunnan University of Traditional Chinese Medicine (R-062016003) (Kunming, China). All reasonable efforts were made to minimize animal suffering.

After one week of adaptive feeding, rats were randomized into four groups ( $n = 5$  rats per group): normal control (normal saline), model (normal saline), simvastatin [1.8 mg/(kg·d)] and *P. kingianum* [4 g/(kg·d)] groups. The simvastatin group served as a positive control. The rats were given the treatments intragastrically once a day for 14 consecutive weeks. Simvastatin and *P. kingianum* were prepared separately in normal saline. Dyslipidemia was induced with an HFD (comprised of 1% cholesterol, 10% refined lard, 10%



**Figure 2** Workflow of the integrated untargeted metabolomic method based on ultra-high performance liquid chromatography/mass spectrometry analysis of serum, urine and liver samples. UHPLC/MS: Ultra-high performance liquid chromatography/mass spectrometry.

eggs and 79% basic feed) for 14 wk in all groups except for the normal control group.

### Sample collection

To collect urine samples, rats in each experimental group were housed in metabolic cages for the last three weeks of the 14 wk of treatment. Samples were collected from the metabolic cages and transferred immediately into sterile tubes. After the last administration at week 14, rats were fasted for 12 h and then anesthetized with chloral hydrate. Fasting blood was collected from the hepatic portal vein, and the liver was harvested and stored at  $-80^{\circ}\text{C}$  until use. Blood samples were allowed to clot at  $4^{\circ}\text{C}$  and centrifuged at  $10000\text{ g}$  for 10 min, after which serum was collected and stored at  $-80^{\circ}\text{C}$  until assayed.

### Measurement of lipid parameters in serum and liver

TG and TC concentrations were determined using  $100\text{ }\mu\text{L}$  of serum and  $100\text{ }\mu\text{L}$  of liver homogenate supernatant, in which the protein concentration was measured by BCA assay. All parameters were evaluated on a SpectraMax Plus 384 Microplate Reader (Molecular Devices, Sunnyvale, CA, United States) using commercially available diagnostic kits in accordance with the manufacturer's instructions.

### Sample pre-treatment for UHPLC/MS analysis

**Serum samples:** Aliquots of serum ( $200\text{ }\mu\text{L}$ ) were diluted with  $600\text{ }\mu\text{L}$  of acetonitrile. After vortex-mixing

and resting at  $4^{\circ}\text{C}$  for 20 min, the samples were centrifuged at  $12000\text{ rpm}$  and  $4^{\circ}\text{C}$  for 15 min. The collected supernatants were dried under a gentle nitrogen stream. The obtained residues were re-dissolved in  $100\text{ }\mu\text{L}$  of acetonitrile for metabolomics analysis.

**Urine samples:** Samples were lyophilized to a powder using a FD5-3 freeze dryer (SIM International Group Co. Ltd., Newark, DE, United States). The obtained sample powders were dissolved with  $100\text{ }\mu\text{L}$  of water and then diluted with  $300\text{ }\mu\text{L}$  of acetonitrile. After vortex-mixing and resting at  $4^{\circ}\text{C}$  for 20 min, the samples were centrifuged at  $12000\text{ rpm}$  and  $4^{\circ}\text{C}$  for 15 min. The collected supernatants were dried with a gentle nitrogen stream. The residues were re-dissolved in  $100\text{ }\mu\text{L}$  of acetonitrile for metabolomics analysis.

**Liver samples:** Samples were thawed at room temperature before pre-treatment. Liver tissue ( $0.2\text{ g}$ ) from each rat was homogenized with  $1.0\text{ mL}$  of normal saline and then diluted with  $300\text{ }\mu\text{L}$  of acetonitrile. After vortex-mixing and resting at  $4^{\circ}\text{C}$  for 20 min, the samples were centrifuged at  $12000\text{ rpm}$  and  $4^{\circ}\text{C}$  for 15 min. The collected supernatants were dried with a gentle nitrogen stream. The residues were re-dissolved in  $100\text{ }\mu\text{L}$  of acetonitrile for metabolomics analysis.

### Conditions of UHPLC/MS analysis

UHPLC/MS analyses were performed on an UHPLC Dionex Ultimate 3000 system coupled with a Thermo



**Table 1** Body weight and food intake of rats

|                         | Normal control | Model          | Simvastatin    | <i>P. kingianum</i> |
|-------------------------|----------------|----------------|----------------|---------------------|
| Initial body weight (g) | 200.87 ± 8.83  | 206.69 ± 8.51  | 205.03 ± 6.26  | 206.72 ± 7.82       |
| Final body weight (g)   | 494.81 ± 37.43 | 518.08 ± 40.50 | 487.62 ± 30.26 | 480.14 ± 29.91      |
| Body weight gain (g)    | 293.94 ± 28.61 | 311.39 ± 31.98 | 282.59 ± 24.01 | 273.42 ± 22.10      |
| Food intake (g)         | 15670.81       | 15042.53       | 14969.08       | 14903.86            |

Values represent the mean ± SD from five animals. *P. kingianum*: *Polygonatum kingianum*.

**Table 2** Effects of *Polygonatum kingianum* on total cholesterol and triglyceride concentrations in rat serum

| Group                     | TC (mmol/L)                | TG (mmol/L)              |
|---------------------------|----------------------------|--------------------------|
| Normal group              | 1.42 ± 0.11 <sup>c</sup>   | 0.91 ± 0.21              |
| Model group               | 1.56 ± 0.11 <sup>a</sup>   | 0.97 ± 0.22              |
| <i>P. kingianum</i> group | 1.43 ± 0.13 <sup>c</sup>   | 0.76 ± 0.13 <sup>c</sup> |
| Simvastatin group         | 1.15 ± 0.09 <sup>b,d</sup> | 0.77 ± 0.09 <sup>c</sup> |

Values represent the mean ± SD from five animals. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 *vs* the relative normal group. <sup>c</sup>*P* < 0.05, <sup>d</sup>*P* < 0.01 *vs* the relative model group. *P. kingianum*: *Polygonatum kingianum*; TC: Total cholesterol; TG: Triglyceride.

Scientific Q-Exactive TM hybrid quadrupole-orbitrap mass spectrometer with a heated-electrospray ionization probe (Thermo Fisher Scientific, San Jose, CA, United States). The UHPLC system consisted of a quaternary pump, an auto-sampler with a temperature control function, a column box, and a photodiode array (PDA) detector.

UHPLC conditions for all samples were: (1) chromatographic column: Thermo C18 column (100 mm × 2.1 mm I.D., 1.9 μm); (2) mobile phase: 0.1% formic acid (A) and acetonitrile (B) with a gradient program (0–3 min, 5% B; 3–5 min, 5% B → 23% B; 5–10 min, 23% B → 43% B; 10–13 min, 43% B → 64% B; 13–16 min, 64% B → 85% B; 16–18 min, 85% B → 100% B; 18–20 min, 100% B → 100% B); (3) flow rate: 0.2 mL/min; and (4) sample injection volume: 4 μL.

MS conditions for all samples were: (1) flow rate: 0.2 mL/min (split from UPLC effluent); (2) detection mode: positive and negative ion; (3) heat block and curved desolvation line temperature: 250 °C; nebulizing nitrogen gas flow: 1.5 L/min; interface voltage: (+) 3.5 kV, (–) –2.8 kV; (4) mass range: MS, *m/z* 100–1000; MS<sup>2</sup> and MS<sup>3</sup>, *m/z* 50–1000; (5) dynamic exclusion time: 10 s; and (6) workstation: Xcalibur 3.0.63 for liquid chromatography combined with data processing, molecular prediction, and precise molecular weight calculations.

### Statistical analysis

Lipid concentrations in serum and liver are expressed as the mean ± standard deviation (SD). Statistical analyses were performed using SPSS software (13.0 for Windows; SPSS, Chicago, IL, United States). Differences between groups were analyzed by one-way analysis of variance (ANOVA, Dunnett's method). *P* < 0.05 (two-tailed) was considered statistically significant.

All UHPLC/MS raw files were exported in Xcalibur Raw File (.raw) format and converted to computable document format (.cdf) with Xcalibur 2.0 software (Thermo Fisher Scientific, Waltham, MA, United States). The converted file was then transferred into XCMS online

(<https://xcmsonline.scripps.edu>) to output all data, including groups and comparisons. After that, multivariate statistical analysis, including principal components analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA), was performed on SIMCA-P 14.1 software (Umetrics, Umeå, Sweden). Potential biomarkers were selected according to the parameters of variable importance in the projection (VIP > 1.0) from OPLS-DA. The metabolites were identified using METLIN database and compared with data reported previously. Finally, biochemical reactions involving the identified metabolites were found through the Kyoto Encyclopedia of Genes and Genomes (KEGG) in MetaboAnalyst4.0 online (<http://www.metaboanalyst.ca>).

## RESULTS

### Effects of HFD and *P. kingianum* on body weight and food intake

In the present study, a HFD rat model was used to investigate the potential effect of *P. kingianum* on HFD-mediated dyslipidemia that was induced by administration of an HFD over a 14-wk period. *P. kingianum* extract was administered by oral gavage at a dosage of 4 g/(kg·d) during HFD administration. During the experiment, none of the rats died, and they had healthy-looking fur, normal drinking habits, moved freely and rapidly responded to external stimuli. As shown in Table 1, the HFD slightly increased body weight, but *P. kingianum* and simvastatin showed a non-significant effect on body weight and food intake.

### Effects of *P. kingianum* on lipids in serum and liver samples from HFD-fed rats

The effects of *P. kingianum* on lipids in serum and liver samples were first assessed in a rat model of HFD-induced dyslipidemia. As shown in Table 2, 14 wk of HFD feeding resulted in a significant increase in TC concentration, but had no significant effect on TG con-

**Table 3** Effects of *Polygonatum kingianum* on total cholesterol and triglyceride concentration in rat liver

| Group                     | TC (mmol/gprot)          | TG (mmol/gprot)          |
|---------------------------|--------------------------|--------------------------|
| Normal group              | 0.77 ± 0.19 <sup>d</sup> | 1.46 ± 0.12 <sup>d</sup> |
| Model group               | 1.17 ± 0.22 <sup>b</sup> | 2.83 ± 0.71 <sup>b</sup> |
| <i>P. kingianum</i> group | 0.95 ± 0.15 <sup>c</sup> | 1.20 ± 0.28 <sup>d</sup> |
| Simvastatin group         | 0.94 ± 0.15 <sup>c</sup> | 1.37 ± 0.43 <sup>d</sup> |

Values represent the mean ± SD from five animals. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 vs the relative normal group. <sup>c</sup>*P* < 0.05, <sup>d</sup>*P* < 0.01 vs the relative model group. *P. kingianum*: *Polygonatum kingianum*; TC: Total cholesterol; TG: Triglyceride.

centration in serum. These effects were significantly reduced by simvastatin, which is known to correct dyslipidemias<sup>[15]</sup>. Similar to simvastatin, *P. kingianum* remarkably prevented HFD-induced dyslipidemias. Furthermore, Table 3 shows that after 14 wk of HFD feeding, hepatic TC and TG concentrations were significantly increased compared with the normal control group. However, these effects were significantly reduced by *P. kingianum* and simvastatin treatment.

#### Metabolomic profiling of serum, urine and liver samples

Separation conditions of the three samples on the UHPLC column were optimized in terms of peak number, peak shape and reproducibility. Figures 3-5 shows representative total ion current profiles of the positive and negative ion modes of the four groups in serum, urine and liver, respectively. A large number of molecules were profiled by UHPLC/MS in the analyzed samples. Moreover, there were significant differences in peak number and intensity between the four groups within each of the three sample types. This indicated different metabolomic states in the different groups. Hence, after 14 wk of HFD feeding and administration of *P. kingianum* and simvastatin, the metabolites in serum, urine and liver samples were significantly different.

#### Multivariate statistical analysis of metabolomic data

PCA and OPLS-DA are frequently used for multivariate data analysis because of their ability to cope with highly multivariate, noisy, collinear and possibly incomplete data. PCA is an unsupervised pattern recognition method that is initially used to discern the presence of inherent similarities in profiles. OPLS-DA is a supervised pattern recognition approach based on a partial least squares algorithm that has higher sensitivity for biomarker detection than other methods.

#### Serum samples

Figure 6A shows the PCA score plots of serum samples in positive and negative ion modes. The normal control, model, simvastatin and *P. kingianum* groups were located in four different regions of the scatter score map. The four sample sets were basically separated. Additionally, the *P. kingianum* group was closer to the normal group than the simvastatin group and partially overlapped with the normal group. This indicated that the composition and concentration of metabolites in the *P.*

*kingianum* group was more similar to the control group. Thus, *P. kingianum* treatment remarkably prevented HFD-induced pathological changes.

OPLS-DA was performed to further verify sample separation from the four groups, to maximize separation between groups and to identify biomarkers from them (Figure 6B). The OPLS-DA score plots were described by the cross-validation parameter, *R*<sup>2</sup>*Y*, and *Q*<sup>2</sup>, which represent the total explained variation for the X matrix and the predictability of the model, respectively. In positive and negative ion modes, the four groups were also significantly separated. The *P. kingianum* and simvastatin groups were both close to the control group, which further indicated that *P. kingianum* treatment strongly prevented HFD-induced pathological changes.


To further evaluate the component changes after treatment, an S-Plot loading diagram was established based on OPLS-DA. As shown in Figure 6C, each point represents a variable that shows the biomarker that caused the difference between the model and *P. kingianum* groups. The importance of each variable to the classification was evaluated by the VIP value, with molecules with a VIP > 1.0 selected as potential biomarkers.

#### Urine samples


Figure 7A shows the PCA score plots of urine samples in positive and negative ion modes. The control group was clearly distinguished from the other three groups, which overlapped partially. In the negative ion mode, there were abnormal sets in the control group, which might be due to individual sample differences that resulted in outlier sample points being outside the 95% confidence interval. The model group was significantly different from the control group. The *P. kingianum* and simvastatin groups had a tendency to deviate from the model group, while the *P. kingianum* group was closer to the cross than the simvastatin group. Compared with the model group, the *P. kingianum* group had a tendency to approach the part samples of the control group and deviate from the part samples of the control group. This was because the appearance of the outlier sample points seriously affected the clustering result. In the positive ion mode, outlier sample points appeared in the control group. The model group had a tendency to deviate to the left compared with the control group. The *P. kingianum* group partially overlapped with the simvastatin group, but did not approach the control group. This was considered to be

# A

I RT: 0.00-25.02




II RT: 0.00-25.02




# B


I RT: 0.00-25.01



II RT: 0.00-25.01



C



**Figure 3** Representative total ion current profiles of serum samples in the negative ( I ) and positive ( II ) ion modes. A: Control group; B: Model group; and C: *Polygonatum kingianum* group.

related to the outlier sample points of the control group.

Figure 7B shows the OPLS-DA diagrams of urine samples in positive and negative ion modes. The results suggested that the samples from all groups were perfectly separated, and samples in each group were well clustered. The *P. kingianum* group was closer to the control group than the simvastatin group, which indicated that *P. kingianum* had significant effects on metabolomic changes in the liver. Figure 8C shows the S-Plot loading diagrams of urine samples and the substances with a VIP > 1.0 that were selected as biomarkers.

### Liver samples

Figure 8A displays the PCA score plots of liver samples in positive and negative ion modes. In the negative ion mode, all samples were distributed within the 95% confidence interval. The control group partially overlapped with the model group, which might be due to the unsupervised pattern recognition of PCA analysis. In the positive ion mode, there were outlier sample points in the control group. The *P. kingianum* group was significantly different from the control and model groups, indicating that *P. kingianum* administration interfered with metabolism in the rats.

Figure 8B showed the OPLS-DA diagrams of liver

samples in positive and negative ion modes. The results suggested that the samples from all groups were perfectly separated, and the samples in each group were well clustered. The *P. kingianum* group was closer to the control group than the simvastatin group, which indicated that *P. kingianum* had significant effects on metabolomic changes in the liver. Figure 8C shows the S-Plot loading diagrams of urine samples and the substances with a VIP > 1.0 that were selected as biomarkers.

### Potential biomarker identification

Nineteen compounds were identified from serum samples, including four in the negative ion mode and 15 in the positive ion mode. They were amino acids, carbohydrates and esters (Table 4). There were 24 compounds identified from urine samples, including seven in the negative ion mode and 17 in the positive ion mode. They were amino acids, organic acids and esters (Table 5). Finally, 38 compounds were identified from liver samples, including 18 in the negative ion mode and 22 in the positive ion mode. They were amino acids, organic acids and esters (Table 6).


### Metabolic pathway analysis

Pathways with influence values greater than 0.1 were selected as the metabolic pathways<sup>[16]</sup>. Pathway impact plots were built to visualize the impact of altered metabolic pathways (Figure 9A). According to these, the




# A

I RT: 0.00-25.01




II RT: 0.00-25.01





# B

I RT: 0.00-25.02



II RT: 0.00-25.02





**Figure 4** Representative total ion current profiles of urine samples in the negative ( I ) and positive ( II ) ion modes. A: Control group; B: Model group; and C: *Polygonatum kingianum* group.

major intervening pathways in serum samples involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and phenylalanine, starch, sucrose, glycerophospholipid, tryptophan and tyrosine metabolism (Figure 9A, Table 7). In urine samples, the major intervening pathway involved arachidonic acid metabolism (Figure 9B, Table 8). In liver samples, the major intervening pathways involved phenylalanine, tyrosine and tryptophan biosynthesis, and arachidonic acid, linoleic acid, nicotinate, nicotinamide, sphingolipid, tryptophan and tyrosine metabolism (Figure 9C, Table 9).

## DISCUSSION

Dyslipidemia is mainly characterized by an increase in TC and TG concentrations in the serum and/or liver. We found that HFD feeding resulted in a significant increase in TC concentration in serum, and in TC and TG concentrations in the liver. This indicated that an HFD could induce hyperlipidemia. *P. kingianum* extract significantly inverted these HFD-induced changes, demonstrating that *P. kingianum* effectively ameliorated dyslipidemia in HFD-fed rats. Additionally, due to fundamental differences in plasma lipoprotein metabolism between rats and humans, it is valuable to use an optimal pathological model

to evaluate the lipid-regulating effects of *P. kingianum*.


Metabolomics has been applied widely to the research of drug efficacy and the associated mechanism of action<sup>[17]</sup>. Currently, the most common samples analyzed in metabolomics are serum, urine, tissues/organs, feces, cells and sub-cells. We used serum, urine and liver samples for metabolomic analysis. The liver is the most important locus for substance metabolism, and also the main site for lipid and amino acid metabolism. External stimuli (e.g. a drug) may cause hepatic metabolites to change affecting the physiological function of the liver<sup>[18]</sup>. Serum reflects the overall status of an organism. When metabolic abnormalities occur in the liver, the metabolites in blood may change through the blood circulation. Urine is an important excretion pathway for metabolites and contains abundant metabolomic information about an organism. Eleven main metabolic pathways affected by *P. kingianum* administration were found in the three samples, including seven in serum and in the liver, and one in urine (Figure 10).

### Phenylalanine, tyrosine and tryptophan biosynthesis and metabolism


Amino acids are the body's raw material for protein synthesis and are catabolic products. They participate in a

# A

I RT: 0.00-30.02




II RT: 0.00-30.02




# B

I RT: 0.00-30.01




II RT: 0.00-30.01




C

I RT: 0.00-30.01



II RT: 0.00-30.01



**Figure 5** Representative total ion current profiles of liver samples in the negative ( I ) and positive ( II ) ion modes. A: Control group; B: Model group; and C: *Polygonatum kingianum* group.

variety of physiological and pathological processes, and their concentration often reflects the metabolic status of the body. In this study, a number of amino acid metabolic pathways were present in the serum and liver samples, with a decrease in these metabolites, indicating disordered amino acid metabolism. Dyslipidemia causes dysfunctional phenylalanine metabolism by inhibiting conversion of phenylalanine to tyrosine, which increases phenylalanine concentration in the blood. After *P. kingianum* administration, we showed decreased phenylalanine and increased tyrosine content in serum. Tyrosine is synthesized from phenylalanine and is necessary for synthesizing catecholamine hormones such as adrenaline (epinephrine). It also plays an important role in promoting energy metabolism, scavenging free radicals and relieving fatigue<sup>[19]</sup>. Tyrosine undergoes a series of metabolic reactions to form acetyl-CoA, which participates in the tricarboxylic acid (TCA) cycle. After *P. kingianum* administration, the tyrosine content was increased, which elevated the acetyl-CoA content and further accelerated lipid decomposition through the TCA cycle. Therefore, *P. kingianum* treatment reduced phenylalanine production and further increased tyrosine production by regulating phenylalanine, tyrosine and tryptophan biosynthesis, and phenylalanine and tyrosine

metabolism.

Tryptophan, an essential amino acid for humans, has important functions for regulating lipid metabolism<sup>[20]</sup>. In addition, tryptophan can be converted to acetyl-CoA to participate in the TCA cycle. After *P. kingianum* administration, the tryptophan content was increased, which potentiated acetyl-CoA content and accelerated lipid decomposition. Thus, *P. kingianum* treatment increased tryptophan content and further relieved the disordered lipids by regulating tryptophan metabolism.


#### **Valine, leucine and isoleucine biosynthesis**

Biosynthesis of valine, leucine and isoleucine was involved in the serum samples. These amino acids can be broken down into glucose. We found that isoleucine was decreased by *P. kingianum* treatment, indicating a reduction in blood glucose. This affected the oxidation and decarboxylation of pyruvate, and further reduced lipid synthesis with glycerol to alleviate the lipid metabolic disorders.

#### **Starch and sucrose metabolism**

Starch and sucrose metabolism was involved in the serum samples. Glucose is the major energy source and metabolic intermediate of living cells. Starch is a






**Figure 6** Multivariate statistical analysis of serum samples from model and *Polygonatum kingianum* groups in the negative (I) and positive (II) ion modes. A: Principal components analysis score plots; B: Orthogonal partial least squares discriminant analysis score plots; C: S-plot loading diagram. PK: *Polygonatum kingianum*.

polysaccharide that is composed of several glucose units. Sucrose is a disaccharide comprised of glucose and fructose molecules. Both sucrose and starch can be broken down into glucose by digestive juice. Glucose can be degraded to dihydroxyacetone phosphate by glycolysis. Dihydroxyacetone phosphate can be reduced to glycerol and can also be converted to pyruvate

through glycolysis. Pyruvate is converted by oxidation and decarboxylation to acetyl-CoA, which can be used to synthesize fatty acids and further synthesize fat with glycerol<sup>[21]</sup>. We found that glucose content was reduced after *P. kingianum* administration, which signified that *P. kingianum* reduced lipid synthesis by regulating starch and sucrose metabolism.




**Figure 7** Multivariate statistical analysis of urine samples from model and *Polygonatum kingianum* groups in the negative (I) and positive (II) ion modes. A: Principal components analysis score plots; B: Orthogonal partial least squares discriminant analysis score plots; C: S-plot loading diagram. PK: *Polygonatum kingianum*.

### Glycerophospholipid metabolism

Glycerophospholipid metabolism was involved in the serum samples. Phosphatidylcholine is the molecule from this pathway that was significantly changed after *P. kingianum* treatment. It is an important component of lipoproteins, a precursor of synthetic cholesterol and it facilitates cholesterol dissolution in bile<sup>[22]</sup>. Phosphati-

dylcholine can also disintegrate TGs and cholesterol in blood and in vascular walls, reducing lipid deposition in the vessel walls. It has been reported that people who eat a high-cholesterol diet with added phosphatidylcholine had lower blood cholesterol concentrations, supporting a hypolipidemic effect of phosphatidylcholine<sup>[23]</sup>. Fat is mainly transported by lipoprotein, while phospho-



**Figure 8** Multivariate statistical analysis of liver samples from model and *Polygonatum kingianum* groups in the negative (I) and positive (II) ion modes. A: Principal components analysis score plots; B: Orthogonal partial least squares discriminant analysis score plots; C: S-plot loading diagram. PK: *Polygonatum kingianum*.

tidylcholine is a vital substance for lipoprotein synthesis. Increased phosphatidylcholine content leads to accelerated hepatic lipoprotein synthesis, which potentiates TG conversion. Thus, insufficient hepatic phosphatidylcholine synthesis is an important contributor to fatty liver. We found that the phosphatidylcholine content was significantly increased after *P. kingianum*

treatment, demonstrating that *P. kingianum* regulated glycerophospholipid metabolism to relieve dyslipidemia.

#### Arachidonic acid metabolism

Arachidonic acid metabolism was involved in the urine and liver samples, and was significantly changed by *P. kingianum* treatment. Cell stimulation results in decom-

**Table 4** Potential biomarkers identified from serum samples

| Retention time (min) | Molecular weight (Da) | VIP     | Potential biomarker                    | Formula   | Change trend<br>Model-PKRP |
|----------------------|-----------------------|---------|--|---|----------------------------|
| ESI-                 |                       |         |  |   |                            |
| 0.928261             | 215.032               | 6.26699 | 2-C-Methyl-D-erythritol 4-phosphate    | C <sub>5</sub> H <sub>13</sub> O <sub>7</sub> P               | down                       |
| 8.30572              | 245.048               | 2.59774 | Pimpinellin                            | C <sub>13</sub> H <sub>10</sub> O <sub>5</sub>                | down                       |
| 17.7034              | 327.233               | 1.53493 | 3-Methyl-5-pentyl-2-furannonanoic acid | C <sub>19</sub> H <sub>32</sub> O <sub>3</sub>                | down                       |
| 13.0574              | 437.291               | 1.03338 | 4,4'-Diaponeurosporene                 | C <sub>30</sub> H <sub>42</sub>                               | up                         |
| ESI+                 |                       |         |  |   |                            |
| 1.11629              | 132.102               | 21.806  | Isoleucine                             | C <sub>6</sub> H <sub>13</sub> NO <sub>2</sub>                | down                       |
| 0.997628             | 132.077               | 16.0576 | 3-Guanidinopropanoate                  | C <sub>4</sub> H <sub>9</sub> N <sub>3</sub> O <sub>2</sub>   | up                         |
| 1.0913               | 118.087               | 14.9589 | Aminopentanoic acid                    | C <sub>5</sub> H <sub>11</sub> NO <sub>2</sub>                | up                         |
| 15.9773              | 496.338               | 14.2141 | LysoPC(16:0)                           | C <sub>24</sub> H <sub>50</sub> NO <sub>7</sub> P             | up                         |
| 2.1554               | 166.086               | 11.8849 | L-Phenylalanine                        | C <sub>9</sub> H <sub>11</sub> NO <sub>2</sub>                | down                       |
| 5.46147              | 205.097               | 10.6298 | L-Tryptophan                           | C <sub>11</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub> | up                         |
| 0.9767               | 203.053               | 10.4336 | α-D-Glucose                            | C <sub>6</sub> H <sub>12</sub> O <sub>6</sub>                 | down                       |
| 18.5687              | 400.332               | 9.59788 | Palmitoyl-L-carnitine                  | C <sub>25</sub> H <sub>45</sub> NO <sub>4</sub>               | down                       |
| 1.09687              | 150.058               | 9.09347 | L-Methionine                           | C <sub>5</sub> H <sub>11</sub> NO <sub>2</sub> S              | down                       |
| 1.10844              | 182.081               | 8.07313 | L-Tyrosine                             | C <sub>9</sub> H <sub>11</sub> NO <sub>3</sub>                | up                         |
| 5.6576               | 202.086               | 6.72953 | 2'-Aminobiphenyl-2,3-diol              | C <sub>12</sub> H <sub>11</sub> NO <sub>2</sub>               | down                       |
| 6.83329              | 160.096               | 6.65796 | 4-Hydroxystachydrine                   | C <sub>7</sub> H <sub>13</sub> NO <sub>3</sub>                | up                         |
| 0.960596             | 140.068               | 6.04106 | Pentanoic acid                         | C <sub>5</sub> H <sub>11</sub> NO <sub>2</sub>                | down                       |
| 15.0993              | 478.306               | 1.00334 | 1-Oleoyl lysophosphatidic acid         | C <sub>21</sub> H <sub>41</sub> O <sub>7</sub> P              | down                       |
| 10.4394              | 288.216               | 2.12052 | L-Octanoylcarnitine                    | C <sub>15</sub> H <sub>29</sub> NO <sub>4</sub>               | down                       |

VIP: Variable importance in the projection.

**Table 5** Potential biomarkers identified from urine samples

| Retention time (min) | Molecular weight (Da) | VIP     | Potential biomarker                               | Formula   | Change trend<br>Model-PKRP |
|----------------------|-----------------------|---------|---|---|----------------------------|
| ESI-                 |                       |         |   |   |                            |
| 9.00895              | 213.113               | 1.42124 | 2,2'-(3-Methylcyclohexane-1,1-diyl) diacetic acid | C <sub>11</sub> H <sub>18</sub> O <sub>4</sub>                | up                         |
| 3.93717              | 218.103               | 1.32234 | Pantothenic acid                                  | C <sub>9</sub> H <sub>17</sub> NO <sub>5</sub>                | up                         |
| 14.0675              | 265.148               | 1.35019 | Cumanin   | C <sub>15</sub> H <sub>22</sub> O <sub>4</sub>                | up                         |
| 1.11379              | 254.981               | 1.3057  | Ascorbate-2-sulfate                               | C <sub>6</sub> H <sub>8</sub> O <sub>6</sub> S                | down                       |
| 0.990052             | 308.099               | 1.2533  | N-Acetylneuraminic acid                           | C <sub>11</sub> H <sub>19</sub> NO <sub>9</sub>               | down                       |
| 3.03597              | 365.135               | 1.15211 | Tetrahydropentoxylone                             | C <sub>17</sub> H <sub>22</sub> N <sub>2</sub> O <sub>7</sub> | down                       |
| 17.8994              | 303.233               | 1.12374 | Arachidonic acid                                  | C <sub>20</sub> H <sub>32</sub> O <sub>2</sub>                | up                         |
| ESI+                 |                       |         |   |   |                            |
| 8.40988              | 173.117               | 1.51559 | 4-Hydroxynonenoic acid                            | C <sub>9</sub> H <sub>16</sub> O <sub>3</sub>                 | up                         |
| 6.14752              | 172.007               | 1.50165 | L-Homocysteine sulfonic acid                      | C <sub>3</sub> H <sub>9</sub> NO <sub>3</sub> S <sub>2</sub>  | up                         |
| 10.4959              | 187.126               | 1.47714 | 1-Phenyl-5-propyl-1H-pyrazole                     | C <sub>12</sub> H <sub>14</sub> N <sub>2</sub>                | up                         |
| 8.40656              | 155.106               | 1.46075 | 4-Oxo-2-nonenal                                   | C <sub>9</sub> H <sub>14</sub> O <sub>2</sub>                 | up                         |
| 8.2458               | 190.115               | 1.44948 | N6-Carbamoyl-DL-lysine                            | C <sub>7</sub> H <sub>15</sub> N <sub>3</sub> O <sub>3</sub>  | up                         |
| 1.89902              | 213.123               | 1.39163 | Butethal  | C <sub>17</sub> H <sub>22</sub> N <sub>2</sub> O <sub>7</sub> | up                         |
| 13.7859              | 256.263               | 1.38483 | Palmitic amide                                    | C <sub>16</sub> H <sub>33</sub> NO                            | up                         |
| 6.67969              | 172.097               | 1.34087 | (3-Methylcrotonyl)glycine methyl ester            | C <sub>8</sub> H <sub>13</sub> NO <sub>3</sub>                | up                         |
| 17.9836              | 315.252               | 1.33499 | 9,10-DiHOME                                       | C <sub>18</sub> H <sub>34</sub> O <sub>4</sub>                | up                         |
| 3.91979              | 220.118               | 1.30061 | Pantothenic acid                                  | C <sub>9</sub> H <sub>17</sub> NO <sub>5</sub>                | up                         |
| 7.08734              | 192.066               | 1.26102 | 5-Hydroxyindoleacetic acid                        | C <sub>10</sub> H <sub>9</sub> NO <sub>3</sub>                | up                         |
| 0.839605             | 146.165               | 1.24838 | Spermidine  | C <sub>7</sub> H <sub>19</sub> N <sub>3</sub>                 | up                         |
| 0.924092             | 170.093               | 1.24502 | 1-Methylhistidine                                 | C <sub>7</sub> H <sub>11</sub> N <sub>3</sub> O <sub>2</sub>  | up                         |
| 1.09509              | 189.123               | 1.23644 | N-Alpha-acetyllysine                              | C <sub>8</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub>  | up                         |
| 9.40433              | 139.112               | 1.20585 | 2-Pentylfuran                                     | C <sub>9</sub> H <sub>14</sub> O                              | up                         |
| 7.33104              | 143.107               | 1.20454 | 2-Octenoic acid                                   | C <sub>8</sub> H <sub>14</sub> O <sub>2</sub>                 | up                         |
| 3.91714              | 222.122               | 1.19506 | Vinyl-L-NIO                                       | C <sub>9</sub> H <sub>17</sub> N <sub>3</sub> O <sub>2</sub>  | up                         |

VIP: Variable importance in the projection.

position of arachidonic acid into a free form by phospholipase A2, with subsequent release into cytosol. The free form produces hundreds of bioactive metabolites by a series of metabolic enzymes. These metabolites have important regulatory effects on lipoprotein metabolism.


Arachidonic acid closely relates to development of hyperlipidemia. In addition to effectively reducing blood lipids, it also decreases malondialdehyde. The latter reflects the degree of lipid peroxidation in tissue cells, indicating that arachidonic acid inhibits lipid peroxidation. Our



**Table 6** Potential biomarkers identified from liver samples

| Retention time (min) | Molecular weight (Da) | VIP     | Potential biomarker   | Formula   | Change trend<br>Model-PKRP |
|----------------------|-----------------------|---------|-----------------------|---|----------------------------|
| ESI-                 |                       |         |                       |   |                            |
| 3.95787              | 218.103               | 9.02621 | Pantothenic acid      | C <sub>9</sub> H <sub>17</sub> NO <sub>5</sub>                | up                         |
| 5.52016              | 203.082               | 5.17533 | L-Tryptophan          | C <sub>11</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub> | up                         |
| 17.9144              | 303.232               | 2.67441 | Arachidonic acid      | C <sub>20</sub> H <sub>32</sub> O <sub>2</sub>                | up                         |
| 8.18557              | 241.073               | 2.08795 | Lumichrome            | C <sub>12</sub> H <sub>10</sub> N <sub>4</sub> O <sub>2</sub> | down                       |
| 17.6944              | 327.233               | 2.03102 | Docosahexaenoic acid  | C <sub>22</sub> H <sub>32</sub> O <sub>2</sub>                | down                       |
| 9.27129              | 201.112               | 1.77891 | Sebacic acid          | C <sub>10</sub> H <sub>18</sub> O <sub>4</sub>                | down                       |
| 18.1942              | 279.232               | 1.75755 | Linoleic acid         | C <sub>18</sub> H <sub>32</sub> O <sub>2</sub>                | up                         |
| 11.3188              | 464.302               | 1.75082 | Glycocholic acid      | C <sub>26</sub> H <sub>43</sub> NO <sub>6</sub>               | down                       |
| 13.9455              | 313.24                | 1.66517 | 9,10-DiHOME           | C <sub>18</sub> H <sub>34</sub> O <sub>4</sub>                | down                       |
| 15.9588              | 319.227               | 1.58662 | 16R-HETE              | C <sub>20</sub> H <sub>32</sub> O <sub>3</sub>                | up                         |
| 7.08734              | 353.234               | 1.56066 | PGE1                  | C <sub>20</sub> H <sub>34</sub> O <sub>5</sub>                | up                         |
| 10.8984              | 227.128               | 1.45155 | Traumatic acid        | C <sub>12</sub> H <sub>20</sub> O <sub>4</sub>                | down                       |
| 2.5168               | 251.079               | 1.41613 | Deoxyinosine          | C <sub>10</sub> H <sub>12</sub> N <sub>4</sub> O <sub>4</sub> | down                       |
| 11.4285              | 221.081               | 1.39399 | Apiole                | C <sub>12</sub> H <sub>14</sub> O <sub>4</sub>                | down                       |
| 16.2815              | 339.199               | 1.28069 | Canrenone             | C <sub>22</sub> H <sub>28</sub> O <sub>3</sub>                | down                       |
| 11.4127              | 351.219               | 1.14883 | PGE2                  | C <sub>20</sub> H <sub>32</sub> O <sub>5</sub>                | up                         |
| 15.6357              | 343.228               | 1.0584  | Medroxyprogesterone   | C <sub>22</sub> H <sub>32</sub> O <sub>3</sub>                | down                       |
| 19.0468              | 281.249               | 1.03242 | Ethyl palmitoleate    | C <sub>18</sub> H <sub>34</sub> O <sub>2</sub>                | down                       |
| ESI+                 |                       |         |                       |   |                            |
| 5.58168              | 205.097               | 25.6421 | L-Tryptophan          | C <sub>11</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub> | up                         |
| 1.12985              | 123.055               | 23.4569 | Niacinamide           | C <sub>6</sub> H <sub>6</sub> N <sub>2</sub> O                | up                         |
| 3.94534              | 220.118               | 15.5283 | Pantothenic acid      | C <sub>9</sub> H <sub>17</sub> NO <sub>5</sub>                | down                       |
| 1.07398              | 244.092               | 13.5445 | Cytarabine            | C <sub>9</sub> H <sub>13</sub> N <sub>3</sub> O <sub>5</sub>  | down                       |
| 1.65458              | 182.081               | 12.3842 | L-Tyrosine            | C <sub>9</sub> H <sub>11</sub> NO <sub>3</sub>                | up                         |
| 0.901697             | 132.077               | 8.82297 | 3-Guanidinopropanoate | C <sub>4</sub> H <sub>9</sub> N <sub>3</sub> O <sub>2</sub>   | down                       |
| 0.990524             | 203.053               | 8.06945 | L-(+)-Gulose          | C <sub>6</sub> H <sub>12</sub> O <sub>6</sub>                 | down                       |
| 2.07851              | 269.088               | 7.66822 | Inosine               | C <sub>10</sub> H <sub>12</sub> N <sub>4</sub> O <sub>5</sub> | down                       |
| 15.0942              | 302.305               | 7.59274 | Sphinganine           | C <sub>18</sub> H <sub>39</sub> NO <sub>2</sub>               | down                       |
| 1.48196              | 153.04                | 7.19394 | Xanthine              | C <sub>5</sub> H <sub>4</sub> N <sub>4</sub> O <sub>2</sub>   | down                       |
| 6.38205              | 130.159               | 6.90221 | Octylamine            | C <sub>8</sub> H <sub>19</sub> N                              | down                       |
| 1.21181              | 150.058               | 6.25979 | L-Methionine          | C <sub>5</sub> H <sub>11</sub> NO <sub>2</sub> S              | down                       |
| 0.83538              | 146.165               | 6.24439 | Spermidine            | C <sub>7</sub> H <sub>19</sub> N <sub>3</sub>                 | down                       |
| 2.90983              | 285.083               | 5.64503 | Xanthosine            | C <sub>10</sub> H <sub>12</sub> N <sub>4</sub> O <sub>6</sub> | down                       |
| 1.64612              | 165.055               | 5.16323 | m-Coumaric acid       | C <sub>9</sub> H <sub>8</sub> O <sub>3</sub>                  | down                       |
| 11.3366              | 181.122               | 4.58665 | Dihydroactinidiolide  | C <sub>11</sub> H <sub>16</sub> O <sub>2</sub>                | down                       |
| 1.14382              | 204.123               | 4.29542 | Succinylmonocholine   | C <sub>9</sub> H <sub>17</sub> NO <sub>4</sub>                | down                       |
| 2.20661              | 218.139               | 4.21655 | Propionyl-L-carnitine | C <sub>10</sub> H <sub>19</sub> NO <sub>4</sub>               | down                       |
| 5.73361              | 114.092               | 3.42289 | ε-Caprolactam         | C <sub>6</sub> H <sub>11</sub> NO                             | down                       |
| 17.9613              | 305.248               | 1.8771  | Arachidonic acid      | C <sub>20</sub> H <sub>32</sub> O <sub>2</sub>                | up                         |
| 13.2435              | 299.201               | 1.60893 | Norethindrone         | C <sub>20</sub> H <sub>26</sub> O <sub>2</sub>                | down                       |
| 11.7171              | 181.122               | 1.58994 | Dihydroactinidiolide  | C <sub>11</sub> H <sub>16</sub> O <sub>2</sub>                | down                       |

VIP: Variable importance in the projection.



**Figure 9** Analysis of metabolic pathways in serum (A), urine (B) and liver (C) samples. a: Phenylalanine, tyrosine and tryptophan biosynthesis; b: Phenylalanine metabolism; c: Valine, leucine and isoleucine biosynthesis; d: Starch and sucrose metabolism; e: Glycerophospholipid metabolism; f: Tryptophan metabolism; g: Tyrosine metabolism; h: Arachidonic acid metabolism; i: Arachidonic acid metabolism; j: Phenylalanine, tyrosine and tryptophan biosynthesis; k: Linoleic acid metabolism; l: Nicotinate and nicotinamide metabolism; m: Sphingolipid metabolism; n: Tryptophan metabolism; and o: Tyrosine metabolism.

Table 7 Results of metabolic pathway analysis of serum samples

| No. | Pathway   | Match status | P value   | Impact  | Details |
|-----|---|--------------|-----------|---------|---------|
| 1   | Phenylalanine, tyrosine and tryptophan biosynthesis | 2/4          | 8.19E-04  | 1.0     | KEGG    |
| 2   | Phenylalanine metabolism                            | 2/9          | 0.0047415 | 0.40741 | KEGG    |
| 3   | Valine, leucine and isoleucine biosynthesis         | 1/11         | 0.126     | 0.33333 | KEGG    |
| 4   | Starch and sucrose metabolism                       | 1/23         | 0.24635   | 0.18783 | KEGG    |
| 5   | Glycerophospholipid metabolism                      | 1/30         | 0.30916   | 0.19753 | KEGG    |
| 6   | Tryptophan metabolism                               | 1/41         | 0.39801   | 0.15684 | KEGG    |
| 7   | Tyrosine metabolism                                 | 1/42         | 0.40552   | 0.14045 | KEGG    |

KEGG: Kyoto Encyclopedia of Genes and Genomes.

Table 8 Results of metabolic pathway analysis in urine samples

| No. | Pathway                     | Match status | P value | Impact  | Details |
|-----|-----------------------------|--------------|---------|---------|---------|
| 1   | Arachidonic acid metabolism | 1/36         | 0.20927 | 0.32601 | KEGG    |

KEGG: Kyoto Encyclopedia of Genes and Genomes.

Table 9 Results of metabolic pathway analysis in liver samples

| No. | Pathway   | Match status | P value  | Impact  | Details |
|-----|---|--------------|----------|---------|---------|
| 1   | Arachidonic acid metabolism                         | 3/36         | 0.042685 | 0.34677 | KEGG    |
| 2   | Phenylalanine, tyrosine and tryptophan biosynthesis | 1/4          | 0.085643 | 0.5     | KEGG    |
| 3   | Linoleic acid metabolism                            | 1/5          | 0.10592  | 1.0     | KEGG    |
| 4   | Nicotinate and nicotinamide metabolism              | 1/13         | 0.25318  | 0.2381  | KEGG    |
| 5   | Sphingolipid metabolism                             | 1/21         | 0.37685  | 0.14286 | KEGG    |
| 6   | Tryptophan metabolism                               | 1/41         | 0.60553  | 0.15684 | KEGG    |
| 7   | Tyrosine metabolism                                 | 1/42         | 0.61452  | 0.14045 | KEGG    |

KEGG: Kyoto Encyclopedia of Genes and Genomes.




Figure 10 Metabolic pathway map of potential biomarkers. The red and blue font represents potential biomarkers that were up- and down-regulated by *Polygonatum kingianum* treatment, respectively. The blue, black and green box represents amino acid, sugar and lipid metabolism, respectively. A: Phenylalanine, tyrosine and tryptophan biosynthesis, and phenylalanine and tyrosine metabolism; B: Tryptophan metabolism; C: Valine, leucine and isoleucine biosynthesis; D: Starch and sucrose metabolism; E: Glycerophospholipid metabolism; F: Arachidonic acid metabolism; G: Linoleic acid metabolism; H: Nicotinate and nicotinamide metabolism; and I: Sphingolipid metabolism. TCA: Tricarboxylic acid.

results showed increased arachidonic acid in the urine and liver samples after *P. kingianum* treatment. Thus, *P. kingianum* regulated arachidonic acid metabolism to alleviate dyslipidemia.

### Linoleic acid metabolism

Linoleic acid metabolism was involved in the liver samples, and linoleic acid was significantly altered with *P. kingianum* treatment. Previous studies found that linoleic acid accelerated fatty acid oxidation and glucose decomposition. Moreover, increased linoleic acid concentrations promoted proliferation and differentiation of fatty cells<sup>[24]</sup>. We found linoleic acid content to be significantly increased after *P. kingianum* administration, suggesting that *P. kingianum* regulated linoleic acid metabolism.

### Niacin and nicotinamide metabolism

Niacin and nicotinamide metabolism was involved in the liver samples. Nicotinamide was the molecule from this pathway that was significantly altered by *P. kingianum* treatment. Nicotinamide is a metabolite produced by amidation of niacin. Niacin reduces synthesis of low density lipoprotein cholesterol, TC and TG, and increases synthesis of high density lipoprotein cholesterol. This indicates that niacin regulates lipid metabolism<sup>[25]</sup>. Our results showed that niacinamide content was increased by *P. kingianum* treatment. This suggests that *P. kingianum* increases niacin to alleviate dyslipidemia by regulating hepatic niacin and nicotinamide metabolism.

### Sphingolipid metabolism

Sphingolipid metabolism was involved in the liver samples. Sphingolipids regulate important cellular functions, with metabolic abnormalities in these lipids closely related to various diseases. Previous studies found that obese individuals have disordered sphingolipid metabolism, which appears as accumulation of sphingolipids (e.g., ceramide) in tissues and blood<sup>[26,27]</sup>. Sphingolipids can be metabolized to sphingosine. In our study, sphingosine content was decreased after *P. kingianum* treatment, suggesting that *P. kingianum* might decrease sphingolipid content to alleviate dyslipidemia by regulating hepatic sphingolipid metabolism.

### Conclusion

Taken together, our data indicated that *P. kingianum* extract alleviated HFD-induced dyslipidemia by regulating a large number of endogenous metabolites in serum, urine and liver. This involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and tryptophan, tyrosine, phenylalanine, starch, sucrose, glycerophospholipid, arachidonic acid, linoleic acid, nicotinate, nicotinamide and sphingolipid metabolism. Thus, *P. kingianum* may be a promising lipid regulator to remedy dyslipidemia and further alleviate its related diseases.

## ARTICLE HIGHLIGHTS

### Research background

Dyslipidemia is an important risk factor for many vicious diseases such as diabetes and cardiovascular disease. Developing dyslipidemia regulators from traditional Chinese medicines (TCMs) to remedy lipid disorders represents attractive strategies for disease therapy. In China, *Polygonatum kingianum* (*P. kingianum*) has been used as an herb and nutritional food for centuries. Known pharmacological activities of *P. kingianum* include immune system stimulation, anti-aging effects and blood glucose regulation.

### Research motivation

To date, studies on the effects of *P. kingianum* on dyslipidemia and the mechanism for these effects have not been investigated.

### Research objectives

We aimed to identify the effects and mechanism of action of *P. kingianum* on dyslipidemia using an integrated untargeted metabolomic method.

### Research methods

A rat model of dyslipidemia was induced with a high-fat diet (HFD) and rats were given *P. kingianum* [4 g/(kg·day)] intragastrically for 14 wk. Changes in serum and hepatic lipid parameters were evaluated. Metabolites in serum, urine and liver samples were profiled using ultra-high performance liquid chromatography/mass spectrometry followed by multivariate statistical analysis to identify potential biomarkers and metabolic pathways.

### Research results

*P. kingianum* significantly inhibited the HFD-induced increase in total cholesterol and low density lipoprotein cholesterol in serum, and total cholesterol and triglyceride in the liver. *P. kingianum* also reduced hepatic high density lipoprotein cholesterol. *P. kingianum* significantly regulated metabolites in the analyzed samples toward normal status. Nineteen, twenty-four and thirty-eight potential biomarkers were identified in serum, urine and liver samples, respectively. These biomarkers involved 11 main metabolic pathways, including seven in serum and in the liver, and one in urine.

### Research conclusions

*P. kingianum* alleviated HFD-induced dyslipidemia by regulating many endogenous metabolites in serum, urine and liver samples. This involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and tryptophan, tyrosine, phenylalanine, starch, sucrose, glycerophospholipid, arachidonic acid, linoleic acid, nicotinate, nicotinamide and sphingolipid metabolism.

### Research perspectives

*P. kingianum* may be a promising lipid regulator to treat dyslipidemia and associated diseases.

## REFERENCES

- 1 Backstone RP. Obesity-related diseases and syndromes: Insulin resistance, type 2 diabetes mellitus, non-alcoholic fatty liver disease, cardiovascular disease, and metabolic syndrome. In: Backstone RP. Obesity: The Medical Practitioner's Essential Guide. Cham: Springer, 2016; 83-108 [DOI: 10.1007/978-3-319-39409-1\_5]
- 2 Naheed DT, Naheed T, Khan A. Dyslipidemias in type II diabetes mellitus patients in a teaching hospital of Lahore, Pakistan. *Pak J Med Sci* 2003; **19**: 283-286
- 3 Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgiou E, Katsimardou A, Karagiannis A. Diabetes and lipid metabolism. *Hormones* (Athens) 2018; **17**: 61-67 [PMID: 29858856 DOI: 10.1007/s42000-018-0014-8]
- 4 Sirtori CR. The pharmacology of statins. *Pharmacol Res* 2014; **88**: 3-11 [PMID: 24657242 DOI: 10.1016/j.phrs.2014.03.002]

- 5 **Caamaño BH**, Diaz JM, Bracho DG, Herrera H, Samur MC. Psychotic Acute Episode and Rhabdomyolysis after Lovastatin Ingestion. *Rev Colomb Psiquiatr* 2012; **41**: 672-679 [PMID: 26572120 DOI: 10.1016/S0034-7450(14)60037-8]
- 6 **Chan K**. Progress in traditional Chinese medicine. *Trends Pharmacol Sci* 1995; **16**: 182-187 [DOI: 10.1016/S0165-6147(00)89019-7]
- 7 **Yang XX**, Gu W, Liang L, Yan HL, Wang YF, Bi Q, Zhang T, Yu J, Rao GX. Screening for the bioactive constituents of traditional Chinese medicines-progress and challenges. *RSC Adv* 2017; **7**: 3089-3100 [DOI: 10.1039/c6ra25765h]
- 8 **Kwon HJ**, Hyun SH, Choung SY. Traditional Chinese Medicine improves dysfunction of peroxisome proliferator-activated receptor alpha and microsomal triglyceride transfer protein on abnormalities in lipid metabolism in ethanol-fed rats. *Biofactors* 2005; **23**: 163-176 [PMID: 16410638 DOI: 10.1002/biof.5520230305]
- 9 **Chen H**, Feng SS, Sun YJ, Yao ZY, Feng WS, Zheng XK. Advances in studies on chemical constituents of three medicinal plants from *Polygonatum* Mill. and their pharmacological activities. *Zhongcaoyao* 2015; **46**: 2329-2338
- 10 **Liu XQ**, Yi H, Yao L, Ma HW, Zhang JY, Wang ZM. Advances in plants of *Polygonatum* and discussion of its development prospects. *Zhongguo Yaoxue Zazhi* 2017; **52**: 530-534
- 11 **Lu JM**, Wang YF, Yan HL, Lin P, Gu W, Yu J. Antidiabetic effect of total saponins from *Polygonatum kingianum* in streptozotocin-induced diabetic rats. *J Ethnopharmacol* 2016; **179**: 291-300 [PMID: 26743227 DOI: 10.1016/j.jep.2015.12.057]
- 12 **Yan H**, Lu J, Wang Y, Gu W, Yang X, Yu J. Intake of total saponins and polysaccharides from *Polygonatum kingianum* affects the gut microbiota in diabetic rats. *Phytomedicine* 2017; **26**: 45-54 [PMID: 28257664 DOI: 10.1016/j.phymed.2017.01.007]
- 13 **Wang Z**, Zhang J, Ren T, Dong Z. Targeted metabolomic profiling of cardioprotective effect of *Ginkgo biloba* L. extract on myocardial ischemia in rats. *Phytomedicine* 2016; **23**: 621-631 [PMID: 27161403 DOI: 10.1016/j.phymed.2016.03.005]
- 14 **Tao Y**, Chen X, Li W, Cai B, Di L, Shi L, Hu L. Global and untargeted metabolomics evidence of the protective effect of different extracts of *Dipsacus asper* Wall. ex C.B. Clarke on estrogen deficiency after ovariectomy in rats. *J Ethnopharmacol* 2017; **199**: 20-29 [PMID: 28132861 DOI: 10.1016/j.jep.2017.01.050]
- 15 **Han W**, Li J, Tang H, Sun L. Treatment of obese asthma in a mouse model by simvastatin is associated with improving dyslipidemia and decreasing leptin level. *Biochem Biophys Res Commun* 2017; **484**: 396-402 [PMID: 28131832 DOI: 10.1016/j.bbrc.2017.01.135]
- 16 **Xie HH**, Xie T, Xu JY, Shen CS, Lai ZJ, Xu NS, Wang SC, Shan JJ. Metabolomics study of aconitine and benzoyleconine induced reproductive toxicity in BeWo cell. *Fenxi Huaxue* 2015; **43**: 1808-1813 [DOI: 10.1016/S1872-2040(15)60881-7]
- 17 **Chen H**, Yuan B, Miao H, Tan Y, Bai X, Zhao YY, Wang Y. Urine metabolomics reveals new insights into hyperlipidemia and therapeutic effect of rhubarb. *Anal Methods* 2015; **7**: 2113-2123 [DOI: 10.1039/c5ay00023h]
- 18 **Kaplowitz N**. Mechanisms of liver cell injury. *J Hepatol* 2000; **32**: 39-47 [PMID: 10728793 DOI: 10.1016/S0168-8278(00)80414-6]
- 19 **Holme E**, Mitchell GA. Tyrosine metabolism. In: Blau N, Duran M, Gibson K, Dionisi Vici C. ed. *Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases*. Berlin, Heidelberg: Springer, 2014; 23-31 [DOI: 10.1007/978-3-642-40337-8\_2]
- 20 **Owasoyo JO**, Neri DF, Lamberth JG. Tyrosine and its potential use as a countermeasure to performance decrement in military sustained operations. *Aviat Space Environ Med* 1992; **63**: 364-369 [PMID: 1599383]
- 21 **Catalano KJ**, Maddux BA, Szary J, Youngren JF, Goldfine ID, Schaufele F. Insulin resistance induced by hyperinsulinemia coincides with a persistent alteration at the insulin receptor tyrosine kinase domain. *PLoS One* 2014; **9**: e108693 [PMID: 25259572 DOI: 10.1371/journal.pone.0108693]
- 22 **Lagace TA**. Phosphatidylcholine: Greasing the Cholesterol Transport Machinery. *Lipid Insights* 2016; **8**: 65-73 [PMID: 27081313 DOI: 10.4137/LPLS31746]
- 23 **Wang TJ**, Larson MG, Vasani RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. *Nat Med* 2011; **17**: 448-453 [PMID: 21423183 DOI: 10.1038/nm.2307]
- 24 **West DB**, Delany JP, Camet PM, Blohm F, Truett AA, Scimeca J. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. *Am J Physiol* 1998; **275**: R667-R672 [PMID: 9728060]
- 25 **Iwaki M**, Murakami E, Kakehi K. Chromatographic and capillary electrophoretic methods for the analysis of nicotinic acid and its metabolites. *J Chromatogr B Biomed Sci Appl* 2000; **747**: 229-240 [PMID: 11103908 DOI: 10.1016/S0378-4347(99)00486-7]
- 26 **Turinsky J**, O'Sullivan DM, Bayly BP. 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. *J Biol Chem* 1990; **265**: 16880-16885 [PMID: 2211599]
- 27 **Samad F**, Hester KD, Yang G, Hannun YA, Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. *Diabetes* 2006; **55**: 2579-2587 [PMID: 16936207 DOI: 10.2337/db06-0330]

**P- Reviewer:** Beltowski J    **S- Editor:** Ma RY    **L- Editor:** Wang TQ  
**E- Editor:** Yin SY







Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045